What is Anamorelin used for in research?

Research on Anamorelin has focused on: Increases appetite and food intake; Improves lean body mass in cachexia; Enhances body weight in wasting conditions; Stimulates growth hormone secretion; Improves physical function in cancer patients; Reduces muscle wasting progression.

What is the typical dose of Anamorelin?

Typical research doses are 50-100 mg, administered 1x daily. Commonly timed: Before first meal. These are research figures only — not clinical recommendations.

What are the known side effects of Anamorelin?

Side effects reported in research include: Increased appetite and food intake (common, mild); Nausea (common, mild); Headache (uncommon, mild); Dizziness or lightheadedness (uncommon, mild); Elevated cortisol levels (uncommon, moderate); Fluid retention (uncommon, mild); Hyperglycemia or impaired glucose tolerance (uncommon, moderate); Abdominal discomfort or cramping (uncommon, mild); Fatigue (rare, mild); Cardiac arrhythmias or palpitations (rare, serious). Always consult a qualified professional before use.

How is Anamorelin administered?

Anamorelin is typically administered via Oral.

What is the evidence quality for Anamorelin?

Anamorelin carries an evidence grade of B. Grade B — supported by human observational studies or smaller trials.

Growth Hormone Secretagogues / Oral

Anamorelin

Q: How should Anamorelin be stored?

Unopened: Store at room temperature (15-25°C / 59-77°F) in original packaging, protected from light and moisture.

Also known as RC-1291, Anavex

An oral ghrelin receptor agonist approved in Japan for cancer cachexia. Stimulates appetite and increases lean body mass in wasting conditions.

What is Anamorelin used for? Research has focused on increases appetite and food intake; improves lean body mass in cachexia; enhances body weight in wasting conditions.

Compare with other peptides studied formuscle growth,fat loss

Evidence grade BResearch only

Beginner basics

Plain-English guide to Anamorelin

What it does: Anamorelin tells your body to increase appetite and helps preserve muscle mass during periods of severe weight loss or wasting. Researchers study it because it can help people eat more and maintain strength when their body is breaking down.
Typical dose: Researchers typically use 50 to 100 mg taken by mouth once per day, starting at the lower dose and adjusting based on how well it works and how the body responds.
When to inject: Take it by mouth before your first meal of the day for best results.
Storage: Keep the tablets or powder at room temperature in a dry place away from light. Once mixed or opened, use within the timeframe specified on the package.
Beginner tip: Start at 50 mg and give your body at least a week or two to adjust before considering a higher dose-this helps you notice whether it's actually working for you.

Research status

Evidence grade B: Smaller human trials, observational studies, or approved in 30 or more countries.
Research only: No regulatory approval in any major jurisdiction. Research use only.

Moderate Clinical Data

For research purposes only. Not approved for human use. Not medical advice.

Research areas

Increases appetite and food intake
Improves lean body mass in cachexia
Enhances body weight in wasting conditions
Stimulates growth hormone secretion
Improves physical function in cancer patients
Reduces muscle wasting progression

Side effects

Effect	How often	Severity
Increased appetite and food intakeIntended therapeutic effect in cachexia; may cause weight gain if caloric intake exceeds expenditure in non-cachectic individuals.	Common	Mild
NauseaOften transient and may diminish with continued use. Taking with food may reduce incidence.	Common	Mild
HeadacheReported in clinical trials; typically mild and self-resolving.	Uncommon	Mild
Dizziness or lightheadednessMay occur early in treatment; advise caution with position changes.	Uncommon	Mild
Elevated cortisol levelsGhrelin agonism may transiently increase cortisol; monitor in patients with adrenal or metabolic concerns.	Uncommon	Moderate
Fluid retentionGH-mediated effects; typically mild and reversible upon discontinuation.	Uncommon	Mild
Hyperglycemia or impaired glucose toleranceGH is diabetogenic; monitor blood glucose in patients with diabetes or prediabetes.	Uncommon	Moderate
Abdominal discomfort or crampingRelated to increased appetite and food intake; usually resolves with dose adjustment.	Uncommon	Mild
FatigueReported infrequently in clinical trials.	Rare	Mild
Cardiac arrhythmias or palpitationsGhrelin agonists may affect cardiac function; contraindicated in patients with uncontrolled arrhythmias or acute cardiac disease. Requires medical evaluation if occurs.	Rare	Serious

Dosing reference

Dose scale from the research

Starting: 50 mg
Upper end: 100 mg

Anamorelin dosing reference
Parameter	Value
Dose range	50-100 mg
Frequency, timing and route are for members Sign up free Log in

Checked October 2026

Research disclaimer. Figures are drawn from published research literature and community logs. They are not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution guide

Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration

Work out your exact dose in the free peptide calculator

Storage and stability

Unopened: Store at room temperature (15-25°C / 59-77°F) in original packaging, protected from light and moisture.

Molecular and pharmacological data

Molecular weight	389.52
Half-life	3-5 hours (oral)
Sequence	Members only

Anamorelin is a selective ghrelin receptor (growth hormone secretagogue receptor 1a) agonist that mimics the action of endogenous ghrelin. It stimulates growth hormone release from the anterior pituitary and increases appetite signaling in the hypothalamus, leading to increased food intake and preservation of lean body mass in catabolic states such as cancer cachexia.

Pathways and mechanism detail are for members

Keep a log of your Anamorelin research

Free account. No credit card required.

Start free Goal finder Interaction checker

Research citations

5 sources

Temel JS, et al. (2016). Anamorelin for loss of appetite in patients with advanced non-small-cell lung cancer: results of a randomized, double-blind, phase 2b trial. Journal of Clinical Oncology. 34(23):2731-2738. PMID: 27269937
Garcia JM, et al. (2015). Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. The Lancet Oncology. 16(1):108-116. PMID: 25467046
Argilés JM, et al. (2018). Ghrelin and cancer cachexia: mechanisms and therapeutic implications. Current Opinion in Clinical Nutrition and Metabolic Care. 21(3):222-227. PMID: 29570070
Kir S, et al. (2016). Ghrelin mediates the beneficial metabolic effects of bariatric surgery in mice. Journal of Clinical Investigation. 126(6):2223-2236. PMID: 27111235
Nagaya N, et al. (2008). Treatment of cachexia with ghrelin in patients with COPD. Chest. 134(4):753-760. PMID: 18842915

All Growth Hormone Secretagogues peptides

Browse the research library

147 peptide profiles and 59 blend profiles with mechanism summaries, dosing data and reconstitution guides.

View all peptides

Stay updated on Anamorelin research

A weekly digest of new peptide research, stack guides and site updates.

Research use only. All content on this page is provided for informational and educational purposes related to scientific research. Anamorelin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.